CompletedNot Applicable

Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure

United Kingdom700 participantsStarted 2013-08-28

Plain-language summary

This study will assess whether percutaneous coronary intervention (angioplasty of the heart arteries) can improve survival and reduce hospitalization in patients with heart failure due to coronary disease, who have been treated with the best contemporary medical therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Poor left ventricular function (EF≤35%)
✓. Extensive coronary disease
✓. Viability in at least 4 dysfunctional segments that can be revascularised by PCI

Exclusion criteria

✕. Myocardial infarction \< 4 weeks prior to randomisation (clinical definition)
✕. Decompensated heart failure requiring inotropic support, invasive or non-invasive ventilation or Intra-aortic Balloon Pump/left ventricular assist device therapy \<72 hours prior to randomization
✕. Sustained Ventricular Tachycardia/Ventricular Fibrillation or appropriate Implantable Cardioverter Defibrillator discharges \<72 hours prior to randomization
✕. Valve disease requiring intervention
✕. Contraindications to percutaneous coronary intervention
✕. Age \<18 yrs
✕. Estimated Glomerular Filtration Rate \< 25 ml/min, unless established on dialysis
✕. Women who are pregnant

What they're measuring

All-cause death or Hospitalization for Heart Failure

Timeframe: 1 to 103 months (min follow-up duration: 24 months)

Trial details

NCT IDNCT01920048

SponsorKing's College London

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-03-19

View on ClinicalTrials.gov More Ischemic Cardiomyopathy trials